Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (noted as Scisparc Ltd. in metadata) covers the month of November 2017. The report details the results of the Annual General Meeting of Shareholders held on November 1, 2017. The company is a foreign private issuer based in Givatayim, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder approvals rather than financial performance data.
Material Changes and Corporate Actions
- Board Composition: Shareholders elected Dr. Ascher Shmulewitz (Chairman), Amit Berger, Dr. Yafit Stark, Zohar Heiblum, Stephen M. Simes, Mark E. Groussman, and Eric So as directors.
- Auditor Appointment: Kost Forer Gabbay & Kasierer (EY Global) was appointed as the independent registered public accounting firm for the year ending December 31, 2017.
- Executive Leadership: Dr. Ascher Shmulewitz was appointed as Interim Chief Executive Officer for no additional consideration.
- License Agreement Amendment: Shareholders approved the Second Amendment to the License Agreement with Dekel Pharmaceuticals Ltd., replacing royalty, sublicense, and milestone payment rights with 19,000,000 Ordinary Shares (475,000 ADSs).
- Compensation Adjustments:
- Directors' annual fees set at NIS 120,000, effective October 1, 2017.
- Retroactive one-time cash payments of $25,000 each to directors Stephen Simes and Abraham Meizler for IPO services.
- Increased monthly consulting fees for Executive Chairman Dr. Ascher Shmulewitz.
- Increased compensation terms for CFO Mr. Josh Blacher, effective April 12, 2017.
- Equity Grants:
- Options granted to Dr. Ascher Shmulewitz for 7,150,000 Ordinary Shares (178,750 ADSs).
- Options granted to Mr. Josh Blacher for 1,900,000 Ordinary Shares (47,500 ADSs).
- Options granted to director nominees and two former directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on market conditions, or specific risk factors. The document is limited to the ratification of past and current corporate decisions.
Investor Verification Checklist
- Verify the dilution impact of the 19,000,000 shares issued to Dekel Pharmaceuticals Ltd. in exchange for royalty rights.
- Confirm the total number of outstanding shares and the percentage ownership of the new equity grants to Dr. Shmulewitz and Mr. Blacher.
- Review the full text of the Amended Compensation Policy and the Second Amendment to the License Agreement referenced in the proxy statement.
- Assess the financial impact of the retroactive cash payments and increased consulting fees on the company's cash reserves.